FDA approval supported by positive results from the pivotal Phase 3 SONICS and LOGICS studies demonstrating Recorlev to be a safe and effective therapeutic option in the treatment of Cushing's syndrome
FDA decision follows successful completion of acquisition of Strongbridge Biopharma on October 5, 2021
Post-acquisition, the Company is well-positioned to address the needs of Cushing’s syndrome patients in the U.S. who are treated with prescription therapy
Commercial launch of Recorlev is planned for Q1 2022
https://finance.yahoo.com/news/xeris-biopharma-announces-u-fda-213000491.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.